Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2022
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) with 1800 Diagonal Lending LLC ("Diagonal").
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial statements. Key metrics related to the transaction include:
- Principal Amount: $105,000
- Net Proceeds: $101,250 (intended for general working capital)
- Transaction Costs: $3,750 (legal fees and due diligence paid to Diagonal)
- Interest Rate: 8% per annum (payable in cash or shares)
- Maturity Date: June 30, 2023
- Conversion Discount: 35% (Variable Conversion Price is 65% of Market Price)
Material Changes
The filing discloses the creation of a new direct financial obligation. The Company entered into a convertible promissory note agreement, creating a liability of $105,000. This represents a material change in the Company's capital structure and debt obligations as of the reporting date.
Terms, Risks, and Contingencies
Conversion Terms: Diagonal may convert the note into common stock starting 180 days after issuance. Conversion is capped at 4.99% of outstanding shares to prevent excessive dilution.
Prepayment Penalties: The note includes significant prepayment premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
Default Provisions:
- Default Amount: Upon certain events of default, the obligation accelerates to 150% of the outstanding principal plus accrued interest.
- Penalty for Non-Delivery: A penalty of $1,000 per day applies if shares are not delivered within three business days of a conversion notice (unless caused by a third party).
- Events of Default: Include failure to reserve shares (5x conversion amount), insolvency, failure to maintain OTC listing, financial restatements, or failure to comply with SEC reporting requirements.
Restrictions: The Company covenants not to sell substantially all assets or become a "shell company" without Diagonal's consent while the note is outstanding.
Investor Verification Checklist
- Verify the closing date of the transaction (expected on or about July 8, 2022) and confirmation of fund receipt.
- Review the full text of the Convertible Promissory Note (Exhibit 4.1) and Securities Purchase Agreement (Exhibit 10.1) for detailed definitions of "Market Price" and "Trading Day."
- Assess the Company's current cash position to determine the ability to service the 8% interest or manage potential prepayment penalties.
- Monitor the Company's compliance with SEC reporting requirements and OTC listing status to avoid triggering default events.
- Calculate potential dilution impact based on the 35% discount rate and the 4.99% beneficial ownership cap.